EPISODE · Sep 9, 2026 · 9 MIN
Insilico Medicine's AI-designed drug is showing early signs it can slow aging—a real-world biotech application
from Onpode
Insilico Medicine, a clinical-stage biotechnology company founded by Alex Zhavoronkov, has published two landmark studies on its AI-designed drug candidate rentosertib (also referred to as INS018_055 or ISM001-055), developed to treat idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung-scarring disease.
Embed this episode
Ready to play
Insilico Medicine's AI-designed drug is showing early signs it can slow aging—a real-world biotech application
0:00
9:37
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Onpode?
This episode is 9 minutes long.
When was this Onpode episode published?
This episode was published on September 9, 2026.
Can I download this Onpode episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!